Literature DB >> 12777471

Determinants of low HDL levels in familial combined hyperlipidemia.

Aino Soro1, Matti Jauhiainen, Christian Ehnholm, Marja-Riitta Taskinen.   

Abstract

In familial combined hyperlipidemia (FCHL), affected family members frequently have reduced levels of HDL cholesterol, in addition to elevated levels of total cholesterol and/or triglycerides (TGs). In the present study, we focused on those determinants that are important regulators of HDL cholesterol levels in FCHL, and measured postheparin plasma activities of hepatic lipase (HL), lipoprotein lipase, cholesterol ester transfer protein, and phospholipid transfer protein (PLTP) in 228 subjects from 49 FCHL families. In affected family members (n = 88), the levels of HDL cholesterol, HDL2 cholesterol, HDL3 cholesterol, and apolipoprotein A-I were lower than in unaffected family members (n = 88) or spouses (n = 52). The main change was the reduction of HDL2 cholesterol by 25.4% in affected family members (P < 0.001 vs. unaffected family members; P = 0.003 vs. spouses). Affected family members had higher HL activity than unaffected family members (P = 0.001) or spouses (P = 0.013). PLTP activity was higher in affected than unaffected family members (P = 0.025). In univariate correlation analysis, a strong negative correlation was observed between HL activity and HDL2 cholesterol (r = -0.339, P < 0.001). Multivariate regression analysis demonstrated that gender, HL activity, TG, and body mass index have independent contributions to HDL2 cholesterol levels. We suggest that in FCHL, TG enrichment of HDL particles and enhanced HL activity lead to the reduction of HDL cholesterol and HDL2 cholesterol.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12777471     DOI: 10.1194/jlr.M300069-JLR200

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  9 in total

1.  Metabolic effects of fluvastatin extended release 80 mg and atorvastatin 20 mg in patients with type 2 diabetes mellitus and low serum high-density lipoprotein cholesterol levels: a 4-month, prospective, open-label, randomized, blinded-end point (probe) trial.

Authors:  Maurizio Bevilacqua; Barbara Guazzini; Velella Righini; Massimo Barrella; Rosanna Toscano; Enrica Chebat
Journal:  Curr Ther Res Clin Exp       Date:  2004-07

2.  The 223A>G polymorphism of the leptin receptor gene and lipid-lowering efficacy of simvastatin in Chinese patients with coronary heart disease.

Authors:  Yan-Ming Sun; Lan-Feng Wang; Jia Li; Zhu-Qin Li; Wei Pan
Journal:  Eur J Clin Pharmacol       Date:  2008-10-16       Impact factor: 2.953

3.  HDL composition regulates displacement of cell surface-bound hepatic lipase.

Authors:  Naghmeh Rouhani; Elizabeth Young; Cynthia Chatterjee; Daniel L Sparks
Journal:  Lipids       Date:  2008-08-01       Impact factor: 1.880

4.  Leptin, leptin gene and leptin receptor gene polymorphism in heart failure with preserved ejection fraction.

Authors:  Tarek A Abd El-Aziz; Randa H Mohamed; Rasha H Mohamed; Heba F Pasha
Journal:  Heart Vessels       Date:  2011-05-17       Impact factor: 2.037

5.  The 223A>G polymorphism of the leptin receptor gene is associated with macroangiopathy in type 2 diabetes mellitus.

Authors:  Run-Tao Gan; Shu-Sen Yang
Journal:  Mol Biol Rep       Date:  2011-09-22       Impact factor: 2.316

6.  Fasting serum triglyceride and high-density lipoprotein cholesterol levels in patients intended to be treated for dyslipidemia.

Authors:  Genovefa D Kolovou; Katherine Anagnostopoulou; Nektarios D Pilatis; Klelia D Salpea; Ioannis S Hoursalas; Ilias Petropoulos; Helen I Bilianou; Dennis V Cokkinos
Journal:  Vasc Health Risk Manag       Date:  2005

7.  APOE and KLF14 genetic variants are sex-specific for low high-density lipoprotein cholesterol identified by a genome-wide association study.

Authors:  Ying-Hui Lee; Ya-Sian Chang; Chih-Chang Hsieh; Rong-Tsorng Wang; Jan-Gowth Chang; Chung-Jen Chen; Shun-Jen Chang
Journal:  Genet Mol Biol       Date:  2022-02-21       Impact factor: 1.771

8.  Haptoglobin inhibits phospholipid transfer protein activity in hyperlipidemic human plasma.

Authors:  Ryan J Henderson; Kishor M Wasan; Carlos G Leon
Journal:  Lipids Health Dis       Date:  2009-07-23       Impact factor: 3.876

Review 9.  Practical guidelines for familial combined hyperlipidemia diagnosis: an up-date.

Authors:  Antonio Gaddi; A F G Cicero; F O Odoo; A A Poli; R Paoletti
Journal:  Vasc Health Risk Manag       Date:  2007
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.